Evidence map›Paper›PMID 40376375›Full record

ArticleCureus2025

Breast Cancer Brain Metastases: A Neurosurgical Point of View From a Single-Center Experience.

Ligia G Tataranu

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Ligia G TataranuNeurosurgery, Carol Davila University of Medicine and Pharmacy, Bucharest, ROU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBrain metastases represent an important factor in breast cancer morbidity and mortality. Although various therapeutic options improved these patients' outcomes, the incidence of this disease is still rising. Several molecular subtypes of breast cancer have been studied, and human epidermal growth factor receptor 2 (HER2) positive and triple-negative breast cancer (TNBC) are more frequently associated with brain metastases. Therefore, anti-HER2 agents have been developed and studied, and they have shown promising results. Nevertheless, in patients with breast cancer brain metastases and acute neurological aggravation, neurosurgery is the primary option and the only one that can immediately reverse the symptoms. In the long run, a multimodal approach involving neurosurgical intervention can positively impact the prognosis. MATERIAL AND

methodsPatients with a confirmed diagnosis of brain metastases from breast cancer (BMBC) between January 2013 and December 2023 were retrospectively reviewed. All patients were newly diagnosed and treated in the 3rd Neurosurgical Department at the Clinical Emergency Hospital, "Bagdasar-Arseni" in Bucharest, Romania. Statistical analyses were carried out and interpreted accordingly.

resultsThe study analyzed 62 patients with BMBC. The median age at diagnosis was 57.19 years, and the most frequently encountered symptoms were represented by headaches, raised intracranial pressure syndrome, and motor deficits. More than 80% of the patients had a Karnofsky Performance Status (KPS) between 80 and 100, and the most associated comorbidities were cardiovascular and type 2 diabetes mellitus. A total of 88.70% of the patients had a single brain metastasis, and the most common localizations were the posterior fossa/cerebellum and frontal lobe. Gross-total resection was possible in 79.03% of the cases, while complications were recorded in 8.06%. Better survival rates were registered in patients of younger ages, with higher KPS, single BM, and smaller tumoral volumes, treated by gross-total resection and by a multimodal approach.

conclusionsNotwithstanding significant advancements in the field of breast cancer, the prognosis of patients with brain metastases remains poor. However, a multimodal approach can prolong survival rates and improve outcomes, while in patients with acute clinical manifestations, neurosurgery remains the only immediate option to reverse the symptoms.

Indexed as

brain metastasesbreast cancermultimodal approachneurosurgeryoutcomes

Identifiers

PMID40376375
PMCPMC12080738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.